Picture loading failed.

Pre-Made Visilizumab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Visilizumab (tentative trade name Nuvion, PDL BioPharma Inc.) is a humanized monoclonal antibody. It is being investigated for use as an immunosuppressive drug in patients with ulcerative colitis and Crohn's disease. Visilizumab binds to the CD3 receptor on certain activated T cells without affecting resting T cells. It is currently under clinical studies for the treatment of ulcerative colitis and Crohn's disease.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-622-1mg 1mg 3090
GMP-Bios-ab-622-10mg 10mg Inquiry
GMP-Bios-ab-622-100mg 100mg Inquiry
GMP-Bios-ab-622-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Visilizumab biosimilar, Whole mAb, Anti-CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody
INN Name Visilizumab
TargetCD3E
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCnd
Highest_Clin_Trial (Jan '20)Phase-III
Est. StatusDiscontinued
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2000
Year Recommended2001
CompaniesPDL BioPharma
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedCrohn's disease;Graft-versus-host disease;Psoriasis;Renal transplant rejection;Ulcerative colitis
Development Techna